Objective WHODAS 2.0 is a unified scale to measuring disability across diseases, countries,
and cultures. The objective was to explore the available evidence on the psychometric …

Introduction There is evidence that low-dose naltrexone (LDN;< 5.0 mg/day) reduces pain
and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no …

In this study we examined the psychometric properties of the World Health Organization
Disability Assessment Schedule (WHODAS 2.0 12-item version) in a mild traumatic brain …

The purpose of this study is to examine the reliability, factor structure, and validity of the
World Health Organization Disability Assessment Schedule (WHODAS 2.0 12 item version) …

Fibromyalgia (FM) is chronic, widespread musculoskeletal pain and accompanying fatigue,
sleep disturbances, cognitive, psychological, and somatic symptoms. The aim of the study is …

To explore the psychometric properties of the Greek version of the World Health
Organization Disability Assessment Schedule (WHODAS 2.0–12 item) in adult patients …

Background: Fibromyalgia syndrome (FMS) is both a challenging and disabling condition.
The International Association for the Study of Pain (IASP) classifies FMS as chronic primary …

BACKGROUND: The World Health Organization Disability Assessment Schedule 2.0
(WHODAS 2.0) 12-item version is a generic self-report instrument measuring perceived …

Abstract ORTEGA-GONZALEZ, Misleydis; AGUIRRE-ACEVEDO, Daniel-Camilo and
JIMENEZ-BENITEZ, Mercedes. Metacognitions on Pain, Functionality and Intensity of Pain in …

BACKGROUND: People with disabilities experience barriers to the labor market. Self-
efficacy is frequently cited as a barrier to engaging in the workforce, and vocational self …